Abstract:1042 Objectives: Receptor interacting protein 1 (RIP1) kinase is a crucial upstream regulator of necroptosis, and the association of RIP1 kinase with a variety of pathologies, such as ischemic injury, inflammatory diseases, and neurodegenerative diseases(PD, MS and ALS), has been investigated. Inhibitors of RIP1 kinase have the potential to provide new therapeutic opportunities to neurodegenerative diseases with significant unmet medical needs. A new 7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine derivative was reported as a novel receptor interacting protein 1 (RIP1) kinase inhibitors. This compound significantly suppressed necroptotic cell death both in mouse and human cells. To investigate the RIP1 kinase regulate functions for the brain disorders, we radiosynthesized [11C]TZ7774 and performed initial in vivo in rodent to determine if [11C]TZ7774 could be a suitable PET radiotracer for imaging RIP1 kinase in the brain. Methods: The radiosynthesis of [11C]TZ7774 was accomplished by N-[11C]methylation of its amide precursor TZ7799 with [11C]CH3I under basic condition (NaOH) in DMF, heated at ~80 oC for 5 min. The radiolabeled product was purified on semi-preparative reversed phase HPLC column combined with solid phase extraction (SPE). The biodistribution study of [11C]TZ7774 was performed using male Sprague Dawley (SD) rats. Animals were euthanized at 5, 30, 60 min post i.v. injection of [11C]TZ7774. Tissues of interests were collected, weighed, and counted on an automated Beckman Gamma counter. The uptake of radioactivity was calculated as percentage injected dose per gram (%I.D./g). Results: The radiosynthesis of [11C]TZ7774 was successfully achieved with good radiochemical yield (30-40%), high chemical and radiochemical purity (> 99%), and high specific activity (> 700 Ci/mmol, decay corrected to EOB). The biodistribution study indicated that the initial brain uptake was high with %ID/gram values of 0.53 at 5 min and then washed out quickly with %ID/gram values of 0.14 at 30 min, and 0.07 at 60 min. Conclusions: Our preliminary biodistribution results suggested that [11C]TZ7774 has good brain uptake. Together, [11C]TZ7774 has great potential to be a PET tracer for imaging RIPK1 in vivo. Further in vitro autoradiography studies and microPET studies of [11C]TZ7774 in animal model of diseases to assess the RIP1 expression response to the progression of disease are ongoing. Research support: NIH/NS075527, NS103988. References: ADDIN EN.REFLIST J. Med. Chem., 2018, 61, 2384-2409; Cell Rep., 2015, 10, 1836-1849; Neural Regener. Res. 2015, 10,1120-1124; Science, 2016, 353, 603-608.

Development of Biochemical and Cellular Probes to Study RIPK1 Target Engagement

[Research Progress on Receptor Interacting Proteins in Inflammation].

Live-cell Imaging and Profiling of C-Jun N-terminal Kinases Using Covalent Inhibitor-Derived Probes.

Design, synthesis, and preclinical evaluation of 11C/18F-labeled inhibitors for RIPK1 PET imaging

Specific Turn-On Fluorescent Probe With Aggregation-Induced Emission Characteristics For Sirt1 Modulator Screening And Living-Cell Imaging

Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity

Design, Synthesis and Biological Evaluation of 4-Aminoquinoline Derivatives As Receptor-Interacting Protein Kinase 2 (RIPK2) Inhibitors

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome

Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors

Preclinical Evaluation of Dihydropyrazole-Cored Positron Emission Tomography (PET) Ligands for Imaging of Receptor-Interacting Serine/Threonine Protein Kinase 1 (RIPK1) in the Brain

Development of Potent and Selective RIPK1 Degraders with In Vivo Efficacy for Cancer Treatment

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Discovery of 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole derivatives as novel RIPK1 inhibitors via structure‐based virtual screening

RIPK2 inhibitors for disease therapy: Current status and perspectives

RIPK2: A Promising Target for Cancer Treatment

Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease

Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs)

Synthesis Andin Vivocharacterization of a Promising 11-Carbon Labeled Receptor Interacting Protein 1 (RIP1) Kinase Radioligand

Ring Closure Strategy Leads to Potent RIPK3 Inhibitors